March 17, 2021 Yamagata, Japan—Metagen Therapeutics Inc. (President and CEO: Taku Nakahara; Headquarters: Yamagata, Japan; hereinafter referred to as ‘MGTx’) which promotes drug discovery and microbiota therapeutics, raised funds through a joint venture between Fast Track Initiative and Keio Innovation. A total of 90M JPY was raised from funds operated by the initiative.
About Metagen Therapeutics
Metagen Therapeutics (MGTx) is a university-launched venture business based out of Yamagata, Japan. The company was founded in 2020 with the mission of “continuing to fulfill the wishes of patients through microbiome science”. MGTx has been accelerating its exploratory research on intestinal microbiomes and its symbiotic relationship with various diseases such as cancer, ulcerative colitis, Crohn’s disease and Parkinson’s disease, aiming to create social impact through medical care and drug discovery. The company is led by top researchers in microbiome science from academic institutions including Juntendo University, Tokyo Institute of Technology, and Keio University. For more information, go to https://www.metagentx.com or follow us on LinkedIn at https://www.linkedin.com/company/metagentx/. For press inquiries or investor inquiries, please email: email@example.com.